von Tobias Borgers | Feb. 14, 2024 | Boehringer
Boehringer Ingelheim is developing a biologicals development centre (BDC) at its facility in Biberach, Germany. Credit: Boehringer Ingelheim. A ground-breaking ceremony for the BDC was held in June 2018. Credit: Boehringer Ingelheim. BDC was inaugurated in April 2023....
von Tobias Borgers | Feb. 14, 2024 | Boehringer
Weltweit führendes Unternehmen der Tiermedizin führt Veeva Vault Clinical und Veeva Vault RIM für mehr Effizienz, Transparenz und Geschwindigkeit ein BARCELONA, Spanien, 14. Februar 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) gab heute bekannt, dass...
von Tobias Borgers | Feb. 2, 2024 | Glaxo
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill became more enamored with synthetic biology—engineering the genetic...
von Tobias Borgers | Feb. 2, 2024 | Glaxo
Omjjara is the first medicine in the EU specifically indicated for treating splenomegaly (enlarged spleen) or symptoms in adult myelofibrosis patients with moderate to severe anaemia Authorisation may address high unmet need, with nearly all myelofibrosis patients...
von Tobias Borgers | Feb. 2, 2024 | Bayer
NAIROBI (Reuters) – Germany’s Bayer will contract a third party to distribute its pharmaceutical products in four African markets including Kenya, it said, adding that the impact on jobs will be minimal. The company, which has 200 employees in the region,...
von Tobias Borgers | Jan. 19, 2024 | Boehringer
Klinische Studien, Biobank-Daten, elektronische Krankenakten, Lieferketten- und Produktionsdaten: In der Pharmabranche stehen unendlich viele Daten bereit. Sie alle haben das Potenzial, uns schneller an das Ziel zu bringen, Menschen und Tieren zu helfen. Mit ihnen...
